The Journal of Trauma: Injury, Infection, and Critical Care · 2020 · 46 citations · 81 references
MedicinePharmacologyPharmacotherapyPatient SafetyTrauma-related DisordersTraumatic Brain Injury PreventionThromboembolic OutcomesThromboembolism PreventionThrombosisThrombosis PreventionTrauma ComplicationsTraumatic InjuryInpatient Venous Thromboembolism PreventionPerioperative Venous Thromboembolism ProphylaxisProphylaxis TimingThromboprophylaxis In Critical IllnessThromboprophylaxis In Hospitalized PatientsThromboprophylaxis In Trauma PatientsTraumatic Brain Injury EpidemiologyVenous Thromboembolism Epidemiology
BACKGROUND: Patients are at a high risk for developing venous thromboembolism (VTE) following traumatic injury. We examined the relationship between timing of initiation of pharmacologic prophylaxis with VTE complications. METHODS: Trauma quality collaborative data from 34 American College of Surgeons Committee on Trauma-verified levels I and II trauma centers were analyzed. Patients were excluded if they were on anticoagulant therapy at the time of injury, had hospitalization <48 hours, or received no or nonstandard pharmacologic VTE prophylaxis (heparin drip). Patient comparison groups were based on timing of initiation of VTE prophylaxis relative to hospital presentation (0 to <24 hours, 24 to <48 hours, ≥48 hours). Risk-adjusted rates of VTE events were calculated accounting for patient factors including type of pharmacologic agent in addition to standard trauma patient confounders. A sensitivity analysis was performed excluding patients who received blood in the first 4 hours and/or patients with a significant traumatic brain injury. RESULTS: Within the 79,386 patients analyzed, there were 1,495 (1.9%) who experienced a VTE complication and 1,437 (1.8%) who died. After adjusting for type of prophylaxis and patient factors, the risk of a VTE event was significantly increased in the 24- to <48-hour (odds ratio, 1.26; 95% confidence interval, 1.09-1.47; p = 0.002) and ≥48-hour (odds ratio, 2.35; 95% confidence interval, 2.04-2.70; p < 0.001) cohorts relative to patients initiated at 0 to <24 hours. These VTE event findings remained significant after exclusion of perceived higher-risk patients in a sensitivity analysis. CONCLUSION: Early initiation of pharmacologic VTE prophylaxis in stable trauma patients is associated with lower rates of VTE. LEVEL OF EVIDENCE: Diagnostic, level III.
81
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine · 2009 · 11.2K citations · Full text
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.9K citations · Full text
VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITY
Glenn W. Brier · Monthly Weather Review · 1950 · 5.3K citations
Business, Mathematics, Meteorology +10
Christopher A. Taylor, Jeneita M. Bell, Matthew J. Breiding et al. · MMWR Surveillance Summaries · 2017 · 2.3K citations · Full text
Medicine, Emergency Medical Services, Emergency Medicine +12